

**Dr M V Copp – Consultant Anaesthetist**

Anaesthetic Department  
Cheltenham General Hospital  
Sandford Road  
Cheltenham  
Gloucestershire  
GL53 7AN

T 0300 422 4143

F 0300 422 3405

E [michael.copp@glos.nhs.uk](mailto:michael.copp@glos.nhs.uk)

15 July 2015

Dear Sir

Manuscript NO: 19770


### **Sugammadex: Role in current Anaesthetic Practice and its safety benefits for Patients**

I wish to respond to the reviewers comments in relation to our submission to the World Journal of Anaesthesia.

I have rewritten the abstract, omitting references, to reflect the content of the article. I am pleased that both reviewers agree that the role of a guideline to help direct clinical use and assist the acceptance by pharmacies of sugammadex onto hospital formularies is important. I have seen many examples of guidelines which are in current use in NHS hospitals. The majority are similar to that presented and based on my original guideline. I do not have any information on how each hospital monitors compliance with their own guidelines or their audit data. I am aware that one or two hospitals have only allowed sugammadex to be used as a rescue drug in the situation of a CICV the implications of which are discussed in the paper.

We have not audited specifically the number of cases using NMB or specifically rocuronium or atracurium and I do not have any precise data on this. I have figures for the costs of reversal agents used during the period of the audit. The audit was a local audit undertaken to simply ensure usage in relevant clinical situations as detailed in the paper and also to reassure hospital and pharmacy managers that a check was in place to ensure responsible usage. I have reviewed the text including some basic numbers of GA's given and the use of NMB to confirm that it is possible to have sugammadex for use without having an adverse effect on the overall operating theatre drug budget. Unfortunately NHS data collection is not sophisticated enough

Chair: Professor Clair Chilvers DSc  
Chief Executive: Dr Frank Harsent PhD,MBA



***Dr M V Copp – Consultant Anaesthetist***

to enable accurate comparison of even simple drug costs between hospitals because of differing budget and management structures.

I hope the paper will inform anaesthetists of where we are today in the responsible administration of sugammadex and an appreciation of the benefits it brings to patients.

I hope you will accept the changes made to the paper and recommend it being published.

Yours sincerely

**Dr M V Copp**  
**Consultant Anaesthetist**

Chair: Professor Clair Chilvers DSc  
Chief Executive: Dr Frank Harsent PhD, MBA

[www.gloshospitals.nhs.uk](http://www.gloshospitals.nhs.uk)

